Haematologica (Jan 2019)

The homeobox transcription factor HB9 induces senescence and blocks differentiation in hematopoietic stem and progenitor cells

  • Deborah Ingenhag,
  • Sven Reister,
  • Franziska Auer,
  • Sanil Bhatia,
  • Sarah Wildenhain,
  • Daniel Picard,
  • Marc Remke,
  • Jessica I. Hoell,
  • Andreas Kloetgen,
  • Dennis Sohn,
  • Reiner U. Jänicke,
  • Gesine Koegler,
  • Arndt Borkhardt,
  • Julia Hauer

DOI
https://doi.org/10.3324/haematol.2018.189407
Journal volume & issue
Vol. 104, no. 1

Abstract

Read online

The homeobox gene HLXB9 encodes for the transcription factor HB9, which is essential for pancreatic as well as motor neuronal development. Beside its physiological expression pattern, aberrant HB9 expression has been observed in several neoplasias. Especially in infant translocation t(7;12) acute myeloid leukemia, aberrant HB9 expression is the only known molecular hallmark and is assumed to be a key factor in leukemic transformation. However, so far, only poor functional data exist addressing the oncogenic potential of HB9 or its influence on hematopoiesis. We investigated the influence of HB9 on cell proliferation and cell cycle in vitro, as well as on hematopoietic stem cell differentiation in vivo using murine and human model systems. In vitro, HB9 expression led to premature senescence in human HT1080 and murine NIH3T3 cells, providing for the first time evidence for an oncogenic potential of HB9. Onset of senescence was characterized by induction of the p53–p21 tumor suppressor network, resulting in growth arrest, accompanied by morphological transformation and expression of senescence-associated β-galactosidase. In vivo, HB9-transduced primary murine hematopoietic stem and progenitor cells underwent a profound differentiation arrest and accumulated at the megakaryocyte/erythrocyte progenitor stage. In line, gene expression analyses revealed de novo expression of erythropoiesis-related genes in human CD34+hematopoietic stem and progenitor cells upon HB9 expression. In summary, the novel findings of HB9-dependent premature senescence and myeloid-biased perturbed hematopoietic differentiation, for the first time shed light on the oncogenic properties of HB9 in translocation t(7;12) acute myeloid leukemia.